Pravastatin in HIV-infected patients treated with protease inhibitors: A placebo-controlled randomized study

HIV Clinical Trials

Volumn 8, Issue 1, 2007, Pages 53-60

  Bonnet, Fabrice ^a,b   Aurillac Lavignolle, Valerie ^b   Breilh, Dominique ^c   Thiébaut, Rodolphe ^b   Peuchant, Evelyne ^a   Bernard, Noëlle ^a   Lacoste, Denis ^a   Dabis, François ^b   Beylot, Jacques ^a   Chêne, Geneviève ^b,d   Morlat, Philippe ^a,b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

HIV; Pravastatin; Protease inhibitors

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CD4 ANTIGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 34047219899     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0801-53     Document Type: Article

References (27)

1. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
2. Thiébaut R, Dabis F, Malvy D, et al. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immun Defic Syndr. 2000;23:261-265.
3. Bonnet F, Savès M, Droz C, et al. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. J Acquir Immun Defic Syndr. 2000;25:199-200.
4. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
5. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
6. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
7. Bonnet F, Balestre E, Thiébaut R, et al. Fibrates or statins and lipid plasma levels in 245 HAART-treated patients. Aquitaine Cohort, France, 1999-2001. HIV Med. 2004;5:133-139.
8. Miller J, Brown D, Amin J, et al. A randomized, double blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS. 2002;16:2195-2200.
9. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS. 2003;17:851-859.
10. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-577.
11. Mallon, PWG, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo controlled study. AIDS. 2006;20:1003-1010.
12. Rouzes A, Berthoin K, Xuereb F, et al. Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry. J Chromatogr B. 2004;813:209-216.
13. Iacona I, Regazzi MB, Buggia I, et al. High-performance liquid chromatography determination of pravastatin in plasma. Ther Drug Monit. 1994;16:191-195.
14. Moyle GJ, Buss NE, Gazzard BG. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. J Acquir Immun Defic Syndr. 2002;30:460-462.
15. Benesic A, Zilly M, Kluge F, et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection. 2004;32:229-233.
16. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004;18:1305-1310.
17. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(suppl 3):50-57.
18. Trenque T, Choisy H, Germain ML. Pravastatin: interaction with oral anticoagulant? BMJ. 1996;312:886.
19. Grau E, Perella M, Pator E. Simvastatin-oral anticoagulant interaction. Lancet. 1996;347:405-406.
20. Ahmad S. Lovastatin-warfarin interaction. Arch Intern Med. 1990;150:2407.
21. Trilli L, Kelley C, Aspinall S, et al. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30:1399-1402.
22. Todd P, Goa K. Simvastatin: a review of its pharmacological properties and potential in hypercholesterolemia. Drugs. 1990;40:583-607.
23. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J Clin Pharmacol. 2000;40:91-98.
24. Watanabe H, Kosuge K, Nishio S, et al. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 2004;76:281-292.
25. Moyle GJ, Lloyd M, Reynolds B, et al. Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS. 2001;15:1503-1508.
26. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147:e18.
27. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.